Therapy Areas: Respiratory
Parnell launches first FDA-approved generic florfenicol and flunixin combination for bovine respiratory disease
1 April 2026 - Veterinary pharmaceutical company Parnell Technologies Pty Ltd on Wednesday announced the US launch of nixiFLOR, an injectable solution approved by the US Food and Drug Administration (...
Frontier Medicines licenses FMC-220 oncology programme to LG Chem in global deal
1 April 2026 - Frontier Medicines Corporation, a clinical-stage precision medicines company, announced on Wednesday that it has entered into an exclusive licensing agreement with South Korean chemical...
ALK secures EU approval for EURneffy 1 mg as needle-free adrenaline option for children
31 March 2026 - Danish pharmaceutical company ALK-Abelló A/S (ALK) (CPH:ALK-B) announced on Tuesday that the European Commission has granted marketing authorisation for EURneffy 1 mg, enabling ...
4DMedical secures EU approval for CT:VQ as EUR83m funding fuels European expansion
30 March 2026 - Cardiothoracic imaging software provider 4DMedical Limited (ASX: 4DX) declared on Monday that it has received CE Mark certification for its CT:VQ imaging technology, enabling commercia...
Almirall reports lebrikizumab demonstrated sustained long-term control in atopic dermatitis through four years
27 March 2026 - Spanish pharmaceutical company Almirall S.A. (BME:ALM) on Friday reported positive long-term interim results from the Phase 3b ADlong study evaluating lebrikizumab in adults and adoles...
AstraZeneca's tozorakimab meets primary endpoints in two Phase III COPD trials
27 March 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) reported on Friday that tozorakimab met the primary endpoint in both the OBERON and TITANIA Phase III trials ev...